Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent reactions, 3′ end processing and strand transfer. Compounds that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication. To characterize the molecular basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs. These studies focused on investigating the role of the conserved carboxylate and metal binding. We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor. Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg 2+ . The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical metal cofactor(s). These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The INSTI pharmacophore consists of a metal chelating core - generally a co-planar triad of oxygen atoms - and a halobenzyl side chain (Fig. 5A, shown in red and blue, respectively)156.”
From Structure and function of retroviral integrase (2022) · cites this paper as [156]
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Self-citationDNA Polymerases: Structural Diversity and Common Mechanisms
Steitz, T. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17395 · Cited by 848
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570
Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., & Davies, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13040 · Cited by 496
Three-Dimensional Structure of the Tn 5 Synaptic Complex Transposition Intermediate
Davies, D. R., Goryshin, I. Y., Reznikoff, W. S., & Rayment, I. (2000) · Science · doi:10.1126/science.289.5476.77 · Cited by 427
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410
Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium
Goldgur, Y., Dyda, F., Hickman, A. B., Jenkins, T. M., Craigie, R., & Davies, D. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9150 · Cited by 380
Sherman, P. A., & Fyfe, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5119 · Cited by 334
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Self-citation
Research works printed but not linked: 1
- P O Brown Retroviruses, eds J M Coffin, S H Hughes, H E Varmus (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 161–203 (1997).
Cited by
Items 301–400 of 443
Integration of human immunodeficiency virus as a target for antiretroviral therapy
Семенова, Е. А., Johnson, A. A., Marchand, C., & Pommier, Y. G. (2006) · Current Opinion in HIV and AIDS · doi:10.1097/01.coh.0000239850.14991.f9 · Cited by 8
New Anti-HIV Agents in Preclinical or Clinical Development
Clercq, E. D. (2003) · Advances in antiviral drug design · doi:10.1016/s1075-8593(03)04001-2 · Cited by 7
Fossey, C., Vu, A.-H., Vidu, A., Zarafu, I., LADUREE, D., Schmidt, S., Laumond, G., & Aubertin, A.-M. (2007) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360701425386 · Cited by 6
Gupta, M., & Madan, A. K. (2012) · Archiv der Pharmazie · doi:10.1002/ardp.201100316 · Cited by 6
Metal Cofactors in the Structure and Activity of the Fowlpox Resolvase
Culyba, M. J., Hwang, Y., Hu, J. Y., Minkah, N. K., Ocwieja, K. E., & Bushman, F. D. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.054 · Cited by 7
“Pendant groups on raltegravir make additional contacts to nearby positions on the integrase surface that confer specificity.(15) Because we are interested in devising poxvirus resolvase inhibitors, we carried out studies to investigate metal atom binding at the active site by the poxvirus resolvase, the likely binding…”
BackgroundFossey, C., Huynh, N. T., Vu, A.-H., Vidu, A., Zarafu, I., LADUREE, D., Schmidt, S., Laumond, G., & Aubertin, A.-M. (2007) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360701425402 · Cited by 5
Ammar, F. F., Hobaika, Z., Abdel‐Azeim, S., Zargarian, L., Maroun, R. G., & Fermandjian, S. (2015) · FEBS Open Bio · doi:10.1002/2211-5463.12025 · Cited by 7
Andrake, M., Ramcharan, J., Merkel, G. W., Zhao, X. Z., Burke, T. R., & Skalka, A. M. (2009) · AIDS Research and Therapy · doi:10.1186/1742-6405-6-14 · Cited by 7
“Although the physiologically relevant cofactor for retroviral IN activity in vivo is believed to be Mg++ [17], both ASV Y A B A”
BackgroundResultKozlov, M. V., Polyakov, K. M., Ivanov, A. V., Filippova, S. E., Kuzyakin, A. O., Tunitskaya, V. L., & Kochetkov, S. N. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906090112 · Cited by 5
Johns, B. A., Kawasuji, T., & Velthuisen, E. J. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737814-00149 · Cited by 6
Gu, W., Martinez, S. E., Nguyen, H. V., Xu, H., Herdewijn, P. A., Jonghe, S. D., & Das, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01747 · Cited by 4
The HIV-1 Integrase: Modeling and Beyond
Arora, R., & Tchertanov, L. (2013) · InTech eBooks · doi:10.5772/52344 · Cited by 5
Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review
Hassounah, S. A., Mésplède, T., & Wainberg, M. A. (2016) · Pathogens and Immunity · doi:10.20411/pai.v1i1.104 · Cited by 6
“INSTIs function by disrupting the interaction between IN and viral and/or target DNA and/or chelating metal ions in the catalytic core domain [23].”
BackgroundLee, G.-E., Kim, J., & Shin, C. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1530969 · Cited by 4
“Amino acid substitution of these residues could affect most activities of IN due to several possible mechanisms, including conformational changes in the FFV IN complex that affects steric hindrance, loss of stabilizing binding interactions, and divalent cation binding [43,44].”
BackgroundYuldasheva, G. A., Zhidomirov, G. M., & Ilin, A. I. (2011) · Natural Science · doi:10.4236/ns.2011.37080 · Cited by 4
“Among the recently developed drugs inhibiting the activity of HIV-1 integrase there are those whose inhibiting activity is connected with the formation of coordination bonds with two Mg ions [12,26] of the catalytic fragment of HIV-1 integrase.”
BackgroundDayer, M. R. (2016) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.29773 · Cited by 4
“formation of functional multimeric assemblies as tetramers or octamers (12-14); and the catalytic core domain (CCD), residues 51 - 212, that contains a conservative catalytic motif of DD35E, which is composed of Asp(64), Asp(116) and Glu(152).”
BackgroundFaridoon, Edkins, A. L., Isaacs, M. L., Mnkandhla, D., Hoppe, H. C., & Kaye, P. T. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.023 · Cited by 4
Strategies for Identification of HIV-1 Integrase Inhibitors
Ramcharan, J., & Skalka, A. M. (2006) · Future Virology · doi:10.2217/17460794.1.6.717 · Cited by 4
“These compounds bind in the active site of an IN–viral DNA complex; mechanistic studies indicate that the adjacent oxygen atoms in the compounds chelate the two active site metal ions in IN to form a tertiary complex that prevents binding of the target substrate [77].”
BackgroundDesign and synthesis of N-hydroxytriazole-4-carboxamides as HIV integrase inhibitors
Bai, Y., Li, L., Wang, X., Zeng, C., & Hu, L. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1136-4 · Cited by 3
“1 for its structure and some typical inhibitors) (Hazuda et al., 2000, 2004; Grobler et al., 2002; Johnson et al., 2004), and to the recent approval of raltegravir (MK-0518) (Summa et al., 2008; Anker and Corales, 2008) and phase II clinical trial of elvitegravir (GS-9137) (Shimura et al., 2008)…”
BackgroundQSAR Study on Diketo Acid and Carboxamide Derivatives as Potent HIV- 1 Integrase Inhibitor
Arodola, O. A., Dash, R. C., & Soliman, M. E. S. (2013) · Letters in Drug Design & Discovery · doi:10.2174/1570180811666131217003010 · Cited by 3
“Thus, the integrase enzyme is crucial for viral replication and represents a potential target for antiretroviral drug design [8-11].”
BackgroundCrosby, D. C., Lei, X., Gibbs, C. G., Reinecke, M. G., & Robinson, W. E. (2015) · Natural Product Communications · doi:10.1177/1934578x1501000129 · Cited by 3
“The observation that many STI, including L-731,988 and L-870,810, bind IN with high affinity and inhibit strand transfer [39, 59] only after formation of an IN-DNA complex suggests a common mechanism of action in which STI trap the IN-DNA synaptic complex in a strand transfer-incompetent state [60].”
BackgroundMartin, S. A., Cane, P. A., Pillay, D., & Mbisa, J. L. (2021) · Pathogens · doi:10.3390/pathogens10091070 · Cited by 3
“One of the later classes of drugs to be approved for clinical use targets the integration of the virus into the host cell genome, specifically the DNA strand transfer reaction [2,3].”
BackgroundHIV Ribonuclease H: Continuing the Search for Small Molecule Antagonists
Wendeler, M., Beilhartz, G. L., Beutler, J. A., Götte, M., & Grice, S. F. L. (2008) · HIV Therapy · doi:10.2217/17584310.3.1.39 · Cited by 4
Kritzyn, A. M., & Komissarov, V. V. (2004) · Russian Journal of Bioorganic Chemistry · doi:10.1023/b:rubi.0000043786.12780.8a · Cited by 3
Influence of Mg2+ ions on the interaction between 3,5-dicaffeoylquinic acid and HTLV-I integrase
Peña, Á., Yosa, J., Cuesta-Astroz, Y., Acevedo, O., Lareo, L., & García‐Vallejo, F. (2012) · Universitas Scientiarum · doi:10.11144/javeriana.sc17-1.iomi · Cited by 3
“Other authors have suggested that there is not enough countercharge in the catalytic domain of the enzyme to allow simultaneous coupling of two divalent cations in adjacent sites (35, 36).”
BackgroundOther Inhibitors of Viral Enzymes and Functions
Zimmermann, H., Hewlett, G., & Rübsamen‐Waigmann, H. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79086-0_6 · Cited by 3
“E of the core domain and compete in binding with the acceptor DNA by chelating the divalent metal ions (Mg2+ and Mn2+, respectively) at the interface of the integrase – viral cDNA complex (Espeseth et al. 2000; Grobler et al. 2002; Hazuda et al. 2004).”
BackgroundRole of Metals in HIV‐1 Integrase Inhibitor Design
Sechi, M., Carcelli, M., Rogolino, D., & Neamati, N. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch20 · Cited by 6
Liao, C., & Nicklaus, M. C. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch28 · Cited by 3
Gordon, C. P., Dalton, N., Vandegraaff, N., Deadman, J. J., Rhodes, D. I., Coates, J. A. V., Pyne, S. G., Griffith, R., Bremner, J. B., & Keller, P. A. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.11.052 · Cited by 2
Komissarov, V. V., Volgareva, G. M., Ol’shanskaya, Y. S., Chernyshova, M. E., Эдуардовна, З. Л., Франк, Г. А., Shtil, A. A., & Kritzyn, A. M. (2009) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162009010105 · Cited by 2
HIV-1 Integrase Strand Transfer Inhibitors
Johns, B. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45016-2 · Cited by 2
Integrase: Um Alvo Terapêutico Importante no Combate à Infecção HIV/AIDS
dos Santos, M. L. A., Albuquerque, M. G., & de Brito, M. A. (2014) · Revista Virtual de Química · doi:10.5935/rvq.v6i4.567 · Cited by 2
Peptidomimetics That Mimic the Tertiary Structures of Peptides
Tamamura, H., Kobayakawa, T., & Ohashi, N. (2018) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-981-10-7691-6_5 · Cited by 2
Elvitegravir, A New HIV‐1 Integrase Inhibitor for Antiretroviral Therapy
Shinkai, H. (2015) · Wiley eBooks · doi:10.1002/9783527678433.ch6 · Cited by 2
Discovery and Development of HIV Integrase Inhibitor Raltegravir
Summa, V., & Pace, P. (2011) · Wiley eBooks · doi:10.1002/9780470929353.ch13 · Cited by 2
Elvitegravir: A Novel Monoketo Acid HIV‐1 Integrase Strand Transfer Inhibitor
Shinkai, H., Sato, M., & Matsuzaki, Y. (2011) · Wiley eBooks · doi:10.1002/9780470929353.ch14 · Cited by 2
Lataillade, M., Chiarella, J., & Kozal, M. J. (2007) · Cited by 1
Retroviral Integrase Structure and DNA Recombination Mechanism
Engelman, A., & Cherepanov, P. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch44 · Cited by 2
Peptidomimetics That Mimic the Secondary Structures of Peptides
Tamamura, H., Kobayakawa, T., & Ohashi, N. (2018) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-981-10-7691-6_4 · Cited by 1
Ebede, G. R., Okoro, E. E., Mbing, J. N., Olofinsan, K. A., Erukainure, O. L., Betote, P. H. D., Pegnyemb, D. E., CHOUDHARY, M. I., Siwe‐Noundou, X., & Ndongo, J. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-68364-0 · Cited by 1
“After an incubation period of 60 min at 37 °C, the plates were washed using PBS containing 0.05% Tween 20 and 0.01% BSA, followed by the addition of peroxidase-conjugated sheep anti-FITC antibody (Thermo Scientific, USA) diluted 1:1000 in the same PBS buffer 24,25 .”
MethodInfluentialConsiderations for Structure-Based Drug Design Targeting HIV-1 Reverse Transcriptase
Arnold, E., Martinez, S. E., Bauman, J. D., & Das, K. (2015) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-94-017-9719-1_6 · Cited by 3
“Recently approved integrase inhibitors (raltegravir and elvitegravir) bind the active site of HIV-1 integrase in a pre-integration complex [5, 6] and block the viral DNA integration into host cell chromosomes.”
BackgroundQSAR-based drug designing studies on HIV-1 integrase inhibitors
Singh, S. P., Deb, C. R., Kakati, L. N., & Konwar, B. K. (2016) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-016-0141-6 · Cited by 1
“And hence, the discovery and development of integrase inhibitors have led to the first FDA approved integrase inhibitor—raltegravir (Fikkert et al. 2003; Grobler et al. 2002; Murray et al. 2007).”
BackgroundResistance to Inhibitors of Human Immunodeficiency Virus Type I Integration
Hazuda, D. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_36 · Cited by 1
“The two novel integrase strand transfer inhibitors to reach advanced clinical development, raltegravir (MK-0518) and elvitegravir (GS-9137, JTK303) (11, 24 , 48, 51) are distinct from the naphthyridines, and each is from a different chemical series (Fig. 6b).”
BackgroundSelf-citationEvaluation of current strategies to inhibit HIV entry, integration and maturation
Reeves, J. D., Barr, S. D., & Pöhlmann, S. (2006) · Springer eBooks · doi:10.1007/978-0-387-31047-3_8 · Cited by 1
“Once bound, the 235 diketo acids compete with the target DNA and inhibit strand transfer, most likely by sequestering the active site metal (Mg2+) (Espeseth et al., 2000; Grobler et al., 2002; Pommier et al., 2005).”
BackgroundInfluentialIntegrase Inhibitors: Possible Future of Anti-HIV/Aids Therapy (A Review)
Akimov, D. V., Filimonov, D. A., & Poroikov, V. (2002) · Pharmaceutical Chemistry Journal · doi:10.1023/a:1022613912158 · Cited by 2
Computer‐Aided Techniques in Design of HIV‐1 Integrase Inhibitors
Serrao, E., Gundla, R., Deng, J. N., Odde, S., & Neamati, N. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch26 · Cited by 1
Resistance to Inhibitors of HIV‐1 Integrase
Hombrouck, A., Clayton, R., Voet, A. R. D., Witvrouw, M., & Debyser, Z. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch30 · Cited by 1
Progress in antiretroviral drugs
Sugiura, W. (2005) · Uirusu · doi:10.2222/jsv.55.85 · Cited by 1
A Study on Drug Resistance Mechanism of HIV-1 Integrase Mutants by Molecular Modeling*
Zhang, X., He, H.-Q., Liu, B., & Wang, C. (2009) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2008.00656 · Cited by 1
Press, B., Daeyaert, F. F. D., Vinkers, H. M., de Jonge, M. R., Heeres, J., Lewi, P. J., & Janssen, P. A. J. (2003) · Cited by 1
Vandekerckhove, L., Christ, F., Debyser, Z., Owen, A., Back, D. J., Voet, A. R. D., Schapiro, J., & Vogelaers, D. (2014) · ASM Press eBooks · doi:10.1128/9781555815493.ch5 · Cited by 1
Biochemical, Structural, And Drug Design Studies Of Multi-Drug Resistant Hiv-1 Therapeutic Targets
Dewdney, T. G. (2013) · Human Biology · Cited by 1
Integrase: Structure, Function, and Mechanism
Dolan, J. R., & Leis, J. P. (2009) · Springer eBooks · doi:10.1007/b135974_21 · Cited by 1
AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy
Zaia, J. A., Cairns, J. S., & Rossi, J. J. (2003) · Wiley eBooks · doi:10.1002/9780470987070.ch100
Raltegravir (Isentress): The First‐in‐Class HIV‐1 Integrase Inhibitor
Hunt, J. A. (2010) · Wiley eBooks · doi:10.1002/9780470768594.ch1
The role of the HIV-1 reverse transcriptase mutation H208Y to drug resistance and viral fitness
Malik, S. A. (2011) · UCL Discovery (University College London)
Dicker, I. B., Walker, M. A., Lin, Z., Terry, B., Pajor, L., Zheng, M., Naidu, B. N., Banville, J., Meanwell, N. A., & Krystal, M. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch19
"Synthesis and Computational Studies on Hiv-1 Integrase Inhibitors"
Sharma, H. (2011) · doi:10.21007/etd.cghs.2011.0285 · Cited by 1
Insights into HIV‐1 Integrase–DNA Interactions
Johnson, A. A., Marchand, C., & Pommier, Y. G. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch7
Elvitegravir: Novel Quinolone HIV‐1 Integrase Strand Transfer Inhibitor
Shinkai, H., Sato, M., & Matsuzaki, Y. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch15
Slow‐Onset Kinetics of HIV Integrase Inhibitors and Proposed Molecular Model
Garvey, E. P., & Schwartz, B. J. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch17
High‐Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition
Fosso‐Kankeu, E., Fonteh, P., & Mishra, A. K. (2013) · Wiley eBooks · doi:10.1002/9781118636299.ch1
A Study on Drug Resistance Mechanism of HIV-1 Integrase Mutants by Molecular Modeling*
Wang, F., Jia-Lie, M. A., Li, H., Chen, X., Wang, Y., & Huang, Q. (2009) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2008.00646
Efficient Cu2+-selective-quinoxalone derivatives Host: Experiment and Theory
Xu, Y., Zeng, C., Zhou, Z., & Zhong, R. (2007) · ICME International Conference on Complex Medical Engineering (CME) · doi:10.1109/iccme.2007.4382025
Anti-HIV agents to be used in drug combination regimens
Clercq, E. D. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7869-2_1
Mukovnya, A. V., Komissarov, V. V., Kritsyn, A. M., Mitkevich, V. A., Tunitskaya, V. L., & Kochetkov, S. N. (2010) · Molecular Biology · doi:10.1134/s0026893310060105
“β Diketones are efficient chelating agents for diva lent metal ions, which determines a high inhibitory activity of some representatives of this class towards HCV RNA dependent RNA polymerase [17–19] and HIV 1 integrase [20–22].”
BackgroundPolimorfismos da região da integrase, do gene pol, em doentes infectados por VIH-1
Cabanas, J. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Emerging Pharmacology: Inhibitors of Human
Hazuda, D. J., Iwamoto, M., & Wenning, L. A. (2009)
Self-citationAdjei-Asante, K. (2014) · University of Liverpool · doi:10.17638/00016073 · Cited by 1
Evaluation of the NIH clinical collection to identify potential HIV-1 integrase inhibitors
Abrahams, S. (2014) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg) · Cited by 2
Recombinant intracellular antibodies for molecular gene therapy of HIV-1 infection
da Silva, F. N. C. A. (2008) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
McGovern, R. A. (2015) · cIRcle (University of British Columbia) · doi:10.14288/1.0166738 · Cited by 1
Hiv Integrase Mechanisms Of Resistance To Raltegravir, Elvitegravir, And Dolutegravir
Ross, K. T. (2015) · Human Biology
Prikazchikova, T. A., Volkov, E. M., Zubin, E. M., Романова, Е. А., & Gottikh, M. (2007)
Huang, Y. B. (2015) · TSpace (University of Toronto)
SERINC5: Its Sensitivity to Nef and Restriction of HIV-1
Dai, W. (2018) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/1ckn-eb15 · Cited by 1
“The mechanism of action of IN inhibitors involves binding to the complex between IN and the viral DNA, as well as interactions with the cofactor Mg2+ in the active site of IN (Grobler et al., 2002).”
BackgroundRecombinant Intracellular Antibodies For Molecular Gene Therapy of HIV-1 Infection
Farmácia, F. D. (2008)
Fluoren-9-ylidene Hydrazine Inhibitors of HIV-1 Ribonuclease H
LaBarge, K. (2011) · D-Scholarship@Pitt (University of Pittsburgh)
Johns, B. A. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc225
Evaluation of current strategies to inhibit HIV entry, integration and maturation
Reeves, J. D., Barr, S. D., & Pöhlmann, S. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-3873-1047-9_8
Carta, F., & Sechi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00006-1
Hussain, E. A., Ghani, A., & Sadiq, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85386-6.00006-8
Okoro, I. S., Umoh, S. D., Asekunowo, A. K., Etim, E. E., Ante, I. E., & Ichôron, N. (2024) · Discover Chemistry. · doi:10.1007/s44371-024-00076-w · Cited by 3
“The previously published protocol [28] served as the model for the HIV-1 subtype C integrase (CIN) strand transfer inhibition assay.”
Développement de molécules antivirales contre les Arenavirus
Mondielli, C. (2018) · theses.fr (ABES) · doi:10.70675/69f00960z9dd9z44d1za615za040059cba77
Identification of specific phylogenetic properties of HIV-1 M and O integrases
Toccafondi, E. (2022) · theses.fr (ABES) · doi:10.70675/2facab6ezc20az472dz8350z9fb6e718e1d4 · Cited by 1
Darazi, P. E. (2021) · theses.fr (ABES) · doi:10.70675/7bb07492ze915z4ca3z845fzba3bb62a3520 · Cited by 1
Non-integrase mechanisms for dolutegravir resistance
Engelman, A. (2026) · Retrovirology · doi:10.1186/s12977-026-00678-5 · Cited by 1
“Structures of INSTI-bound CSC inta-somes revealed that drug heteroatoms engage the active site-bound metal ions, as initially concluded from solution-based biochemical measurements [63].”
Targeting HIV-1 integrase: A review of options, challenges and future directions
Bourquin, R. A., & Schaeffer, P. M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153092 · Cited by 1
HIV cure: from early therapies to cutting-edge strategies
Safaei, Z., & Khalili, K. (2026) · Journal of NeuroVirology · doi:10.1007/s13365-026-01343-5
“InSTIs prevent viral DNA integration by chelating magnesium ions at the integrase active site (Arts and Hazuda 2012; Grobler et al. 2002; Hazuda et al. 2004); PIs block polyprotein cleavage, halting virion maturation (Arts and Hazuda 2012; Miller 2001 ; Park and Morrow 1993); and fusion inhibitors,…”
BindingDB (2013) · UC San Diego · doi:10.7270/q2xw4kvq
Metadata
- Authors
- Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., & Hazuda, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tufts University (US)
- Corresponding author
- Hazuda, Daria J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-05-07
- Volume
- 99
- Issue
- 10
- Pages
- 6661-6666
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC124459
- OpenAlex
- W2117959947
- Cited by
- 399
- References
- 32
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 4 · 2018: 13 · 2017: 8 · 2016: 12 · 2015: 18 · 2014: 17 · 2013: 18 · 2012: 26
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HIV-1 integrase, strand transfer inhibition, metal-dependent enzyme activity, magnesium cofactor, carboxylate binding, reverse transcription, inhibitor mechanism of action
- MeSH terms
- Binding, Competitive, Humans, Ligands, Magnesium, Manganese, Models, Chemical, Phosphotransferases, Styrenes, Molecular Structure, HIV-1, HIV Long Terminal Repeat, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Streptavidin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.